About GELCLAIR Clinical studies

In several clinical trials Gelclair® showed good results in term of:

  • reduction of pain and improvement of ability to eat and drink
  • reduction of the severity of mucositis
  • impact on quality of life (QoL) and acceptability of the product by patients

Of particular relevance is the study by Flook et al., in which Gelclair® was shown to be better tolerated and at least as effective as benzydamine, a topical FANS widely used for mucositis therapy and recommended by the MASCC/ISOO guidelines for patients undergoing RT.

D'Andrea et al. The D'Andrea study, performed on 53 patients receiving therapy for cancer, showed that Gelclair® is an effective intervention in terms of improvements in pain, functionality, and grade of mucositis.  
Read more          
Lindsay G et al. The Linsay et al. study demonstrated a significant efficacy of Gelclair® in reducing pain scores in 33 head and neck cancer patients with oral mucositis receiving radiotherapy.
Read more          
De Cordi D et al. The study demonstrated the efficacy of Gelclair® in patients undergoing different chemotherapy treatments. 
Read more          
Flook C et al. Gelclair® was shown to be at least as effective as benzydamine (recommended for the treatment of oral mucositis caused by radiotherapy by MASCC guidelines) in managing pain caused by oral mucositis.
Read more          
HELSINN This website is for Ex U.S. residents only Last Update: 19.02.2018
Sitemap Privacy and Cookies Policy Terms of Use